Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Bifidobacterium→

Bifidobacterium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Probiotic bacterial genuslive microbial biotherapeutic ingredient
Mechanism of action
May contribute to gut microbial community function, fermentation of carbohydrates and production of short-chain fatty acids. Clinical effects are strain-specific and cannot be generalised from the genus name alone.
Indications / reported uses
  • Use in selected probiotic products for gastrointestinal health or prevention of antibiotic-associated diarrhoea where supported by the specific strain and product authorisation; no single therapeutic indication can be assigned to all Bifidobacterium species or strains

Sources: NIH NCCIH — Probiotics: what you need to know · PubMed — Bifidobacterium strain-specific clinical evidence · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Probiotic bacterial genus; live microbial biotherapeutic ingredient

Mechanism of action

May contribute to gut microbial community function, fermentation of carbohydrates and production of short-chain fatty acids. Clinical effects are strain-specific and cannot be generalised from the genus name alone.

General use cases

  • Use in selected probiotic products for gastrointestinal health or prevention of antibiotic-associated diarrhoea where supported by the specific strain and product authorisation; no single therapeutic indication can be assigned to all Bifidobacterium species or strains

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Bifidobacterium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Bifidobacterium Permitted Daily Exposure (PDE) report (the Bifidobacterium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Bifidobacterium Occupational Exposure Limit (OEL) report (the Bifidobacterium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.